NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials

Summary: The authors of this level-1 study evaluated 2 Phase III, multicenter, double-blind, randomized trials reporting the results of a ready-to-use liquid formulation of nivobotulinumtoxinA for treating moderate-to-severe glabellar lines (GL), with or without lateral canthal lines (LCL). Participants received either nivobotulinumtoxinA or placebo, followed by open-label or continued blinded treatments. At Day 30, significantly more patients treated with nivobotulinumtoxinA achieved ≥2-grade improvement and "none or mild" wrinkle severity ratings compared to placebo (all P < .001). Efficacy was consistent across both studies, and the treatment was well tolerated with similar adverse event rates between groups.